Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Pharmaceutical Executive December 1, 2010 Walter Armstrong	Hyperlipidemia: The Anti-CETPs Redux The crowded cholesterol-control category is the biggest US drug market, with 2010 global sales close to $35 billion, according to IMS Health.
Chemistry World August 23, 2007 Richard Van Noorden	How Good Cholesterol Turns Bad Chemists have peered into the depths of HDL, which protects against heart disease, to explain why it can become harmful. The research may also suggest an explanation for the near-billion-dollar failure of Pfizer's blockbuster heart drug, torcetrapib, in recent clinical trials.
The Motley Fool August 24, 2011 Brian Orelli	Can Roche and Merck Succeed Where Pfizer Failed? CETP inhibitors are lucrative but risky.
The Motley Fool December 4, 2006 Michael P. Cecil	Pfizer's Cholesterol-Drug Hopes Crumble In surprising and disappointing news, the pharma's promising new drug fails clinical trials. With Pfizer shares declining because of the bad news, is now a good time to buy?
Chemistry World January 2007 Derek Lowe	Opinion: In the Pipeline Here is a look at the recent failure of Pfizer's cholesterol drug, torcetrapib, and what it could mean for the future of pharmaceutical research.
The Motley Fool October 5, 2007 Brian Orelli	Merck's Next Blockbuster? Merck's cholesterol drug comes back from phase 2 testing with no side effects. Investors, take note.
The Motley Fool December 1, 2009 Robert Steyer	Merck Makes a Mark on Good Cholesterol Can't profit from fighting bad lipoproteins? Start boosting the good ones.
The Motley Fool November 15, 2011 Brian Orelli	Good Data, Big Drug Market, but Still Risky Eli Lilly's evacetrapib is behind Roche and Merck.
BusinessWeek March 11, 2010	Four Ways to Raise HDL Four different routes to raising good cholesterol.
BusinessWeek March 11, 2010 Ellen Gibson	The Quest to Boost Good Cholesterol Cleveland Clinic's Steven Nissen is again pursuing a drug that will attack plaque by raising HDL.
Chemistry World August 27, 2015 Phillip Broadwith	Drugs in a class of their own In the last month, three drugs in new therapeutic classes have been approved for cardiovascular diseases.
Chemistry World January 19, 2009 Manisha Lalloo	Synthetic HDL could boost body's 'good cholesterol' US scientists say gold nanoparticle based therapies could be used to help boost levels of good cholesterol in our bodies.
HHMI Bulletin May 2011 Sarah C. P. Williams	The Next Statin Although clinicians have firmly established the link between cholesterol levels and heart disease, there are still more questions than answers when it comes to the nitty-gritty molecular details of this connection.
BusinessWeek December 13, 2004 Kate Murphy	Cholesterol: The Bigger the Better Many doctors are convinced that getting a more thorough cholesterol test, one that identifies the types of LDL particles, can improve treatment and save lives.
BusinessWeek April 19, 2004 Catherine Arnst	Cholesterol: How Low Should It Be? New studies say as low as possible, but drugs aren't for everybody
The Motley Fool December 23, 2003 Arash Mostaghimi	The Cholesterol Wars Who will win the fight to save your arteries? Fortunately for our corpulent country, pharmaceutical companies want to unclog our arteries -- and lighten our wallets. But which pharma stock will add to most girth to a portfolio?
American Family Physician January 15, 2001	Goals for Lowering Your Cholesterol Why is it important to have a normal cholesterol level?... What does the term "total cholesterol" mean?... Why is LDL called the "bad" cholesterol?... What are normal cholesterol levels?... How can I reduce my LDL and total cholesterol levels?... etc.
BusinessWeek November 24, 2010 Tom Randall	Merck May Have a Cholesterol Winner Merck told doctors at the American Heart Assn. annual meeting that new data showed its drug anacetrapib had reduced bad cholesterol by 40 percent while raising good cholesterol by an unprecedented 138 percent.
The Motley Fool December 30, 2003 Arash Mostaghimi	Turning Cholesterol Into Cash With 62 million Americans suffering from heart disease, it's a huge target for major drug makers.
American Family Physician January 15, 2002 Lori J. Mosca	Optimal Management of Cholesterol Levels and the Prevention of Coronary Heart Disease in Women Elevated levels of low-density lipoprotein cholesterol and triglycerides and low levels of high-density lipoprotein cholesterol are significant risk factors for coronary heart disease. Abundant data show inadequate utilization of lipid-lowering therapy in women...
Health January 2008 Jessica Snyder Sachs	What You Must Know About Your Cholesterol Many of us are in the danger zone, and we don't realize it. What can we start to do right now to change that?
American Family Physician December 15, 2000 Alan J. Garber	Attenuating Cardiovascular Risk Factors in Patients with Type 2 Diabetes All cardiovascular risk factors except smoking are more prevalent in patients with type 2 diabetes. In addition to exercise, weight control, aspirin therapy and blood pressure control, therapy to modify lipid profiles is usually necessary...
American Family Physician April 15, 2003	Cholesterol What is cholesterol?... Why is a high cholesterol level unhealthy?... When should I start having my cholesterol level checked?... Are there different kinds of cholesterol?... What can I do to improve my cholesterol level?... etc.
American Family Physician March 1, 2002 Richard S. Safeer	Cholesterol Treatment Guidelines Update In addition to modifying current strategies of risk assessment, the new guidelines stress the importance of an aggressive therapeutic approach in the management of hypercholesterolemia...
American Family Physician March 15, 2005 Lockman et al.	Treatment of Cholesterol Abnormalities The relationship between coronary heart disease and elevated cholesterol levels has been recognized for many years, but now studies show an improvement in patient-oriented outcomes in patients receiving drug therapy.
The Motley Fool January 17, 2008 Michael P. Cecil	2 Sources of Trouble for Vytorin You know that a drug study has gone very, very bad when you can't find out its results without a congressional inquiry.
The Motley Fool August 30, 2007 Brian Orelli	Merck Tries to Stop the Flushing The FDA will review the pharma's new cholesterol drug. The biggest worry with getting CORDAPTIVE approved is probably not with its effectiveness, but with safety. Investors, take note.
Nutrition Action Healthletter October 2001	Read My Lipids How to lower your risk of a heart attack...
American Family Physician October 15, 2003 Gavin et al.	Reducing Cardiovascular Disease Risk in Patients with Type 2 Diabetes By increasing patient awareness of the link between diabetes and heart disease, family physicians can encourage patients to take medications (including aspirin), stop smoking, lower blood pressure, and lower cholesterol and blood glucose levels.
American Family Physician January 15, 2001 Michael A. Crouch	Effective Use of Statins to Prevent Coronary Heart Disease Primary and secondary prevention trials have shown that use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (also known as statins) to lower an elevated low-density lipoprotein level can substantially reduce coronary events and death from coronary heart disease...
Managed Care April 2004 Jack McCain	Statin Therapy: More Than Meets the Eye? Statin selection has just become more complicated. Will physicians be diverted from interventions that may be less costly and just as effective?
The Motley Fool November 16, 2009 Brian Orelli	Abbott Puts a Nail in Merck's Coffin There's a clear winner from the American Heart Association conference.
Pharmaceutical Executive November 1, 2014 Josh Baxt	2015 Pipeline Report: Burning Bright The science of drug discovery is back on script and the stars are cued up for a new generation of breakthrough therapies.
Nutra Solutions July 1, 2005	Lowered LDL Study finds that subjects with moderately high cholesterol experienced a 6% drop in total cholesterol after taking a 5g daily dose of an immunoglobulin protein isolate over a period of three weeks.
American Family Physician October 15, 2006 Sharonne N. Hayes	Preventing Cardiovascular Disease in Women The American Heart Association guidelines for cardiovascular disease prevention in women provide physicians with a clear plan for assessment and treatment of cardiovascular disease risk and personalization of treatment recommendations.
The Motley Fool May 27, 2011 Brian Orelli	AIM-HIGH? These Drugmakers Better Duck. A government study on cholesterol drugs hurts Abbott and Merck.
Pharmaceutical Executive December 1, 2005 Ron Feemster	The PharmExec 2005 Pipeline Report Dry? Not quite. Instead of 1990s-style blockbusters, pharma's new molecules are niche drugs, cancer treatments and -- at last -- innovative mechanisms for troublesome targets: Acomplia [rimonabant] by Sanofi-Aventis... AMG 162 [denosumab] by Amgen... etc.
Pharmaceutical Executive December 1, 2010 Walter Armstrong	The Next Wave: Pharm Exec's 2011 Pipeline Report 42 of the best new drugs in development or parked at the FDA
Managed Care December 2007 Ed Silverman	Drugs to Plan For in 2008 There are not many traditional medications in the pipeline, and those that are in development probably won't make waves.
Pharmaceutical Executive December 1, 2006	Pipeline 32 compounds that are the early fruit of pharma's investment in targeted drug design.
The Motley Fool August 23, 2004 Ben McClure	Rethinking Big Pharma Risk is knocking Big Pharma stocks down. They won't be getting up anytime soon. Competition, soaring R&D costs, shifting business models, and political meddling combine to make drug stocks a riskier place to invest.
Pharmaceutical Executive November 1, 2012	Pharm Exec's 2013 Pipeline Report In this year's report, Ben Comer reveals that drug approvals are up, as new discoveries in biology peel away symptomology to expose underlying causes.
The Motley Fool September 24, 2010 Brian Orelli	Prepare for This $12 Billion Whoosh Pfizer's Lipitor is the top-selling cholesterol drug -- in fact, it's the top selling drug period -- but it'll start to see generic competition in a little over a year.
The Motley Fool March 16, 2004 David Nierengarten	Sanofi Slimming Pill Sanofi's new drug, Acomplia, shows promise for weight loss and smoking cessation.
Health February 2007 Eric Steinmehl	The Latest Medial Breakthroughs for the Heart Last year's biggest medical advances are changing the face and future of your health. Here's what you need to know - now!
American Family Physician March 15, 2005	What Should I Know About Cholesterol? A patient hand-out on how cholesterol levels effect the likelihood of heart attack and stroke.
American Family Physician June 15, 2004 Darwin Deen	Metabolic Syndrome: Time for Action Family physicians can be more effective in helping patients to change their lifestyle behaviors by assessing each patient for the presence of specific risk factors, clearly communicating these risk factors to patients, identifying appropriate interventions to address specific risks, and assisting patients in identifying barriers to behavior change.
Nutra Solutions July 1, 2005 Keating & Leigh	Heart-healthy Ingredients: The Beat Goes On Nutraceutical companies respond to cardiovascular disease with products that control cholesterol levels, increase fiber intake and contain omega-3s, phytosterols, garlic and other beneficial ingredients.
BusinessWeek February 28, 2005 Amy Barrett	Pfizer Is "At a Fork in the Road" CEO Henry McKinnell discusses the drugmaker's outlook, from new products and advertising to the challenges facing health care.
Chemistry World May 2008 Derek Lowe	In the pipeline The controversy over cholesterol drug Vytorin has been going on for months. Surveying the wreckage, my first thought is: what a terrible shame the whole affair is.